ArticleWorld journal of surgical oncology2026
CLTC expression in oral squamous cell carcinoma: insights into prognostic value and immune microenvironment modulation.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) has a poor prognosis because of its high metastatic potential and frequent chemoresistance. Although CLTC is aberrantly expressed and involved in fusion events in several tumors, its role in OSCC remains poorly defined.
methodsWe integrated transcriptomic and clinical data from TCGA and GEO, scRNA-seq data, immune infiltration analysis, ligand-receptor based cell-cell communication analysis, drug sensitivity prediction, molecular docking, and in vitro functional validation to evaluate CLTC expression, prognostic value, and its association with the OSCC immune microenvironment.
resultsCLTC was significantly overexpressed in OSCC and several other cancers. High CLTC expression was associated with poorer survival and improved prognostic stratification when combined with tumor mutation burden (TMB). Immune analyses showed that high CLTC expression was associated with reduced CD8 + T-cell infiltration, decreased cytotoxic activity, and increased immune exclusion- and suppression-related signatures. Single-cell analysis showed that CLTC was broadly expressed across OSCC cell populations, with relatively high expression in epithelial, inflammatory epithelial, macrophage, inflammatory macrophage, and endothelial cells. Macrophage-centered communication analysis further revealed prominent MIF-, CXCL-, and SPP1-related signaling interactions between macrophages and tumor, stromal, and immune cell populations. Drug sensitivity prediction and molecular docking suggested potential associations between CLTC expression and responses to several chemotherapeutic agents, although these computational results indicate possible physical interactions rather than confirmed functional drug effects. In vitro experiments confirmed that CLTC was upregulated in OSCC tissues and that CLTC knockdown suppressed SCC25 cell proliferation, migration, and invasion.
conclusionCLTC may serve as a prognostic biomarker in OSCC and may contribute to tumor progression by promoting malignant cellular phenotypes and immunosuppressive remodeling of the tumor microenvironment. Future mechanistic studies are required to determine whether CLTC directly regulates chemotherapy response through clathrin-mediated trafficking, receptor recycling, adhesion signaling, or tumor-immune interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.